Cardiovascular Risk in Prostate Cancer Patients Who Receive Hormone Therapy

Androgen-deprivation therapy (ADT), in combination with external-beam radiotherapy, is a mainstay for managing patients who have localized prostate cancer with adverse features. Data exist to support concomitant and adjuvant ADT durations ranging from 6 months to 3 years in various patient subsets who undergo radiotherapy. In contrast, no compelling data exist to support the role of neoadjuvant ADT in patients who will undergo radical prostatectomy, and recent observational findings have suggested that patients with locoregional disease who are treated with ADT are at risk for developing diabetes and cardiovascular disease.

Investigators used the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database to investigate wh…